News

In surgery for localized muscle-invasive bladder cancer, extended lymph node removal offers no survival benefit but does increase morbidity

The NCTN group chairs propose improvements in how we do correlative science

A new validated risk model identifies advanced cancer trial patients at highest risk for acute care use

Adding ruxolitinib to TKI treatment for chronic-phase chronic myeloid leukemia (CML) increases deep molecular response rate

S1712 finds adding ruxolitinib increases response to TKIs in CML

Some trial results change the standard of care, while others affirm it. Both are valuable.

DART shows success in another rare cancer, and DART II is in the works

That's your PRO Core. Here's a five-year success update.